Subcutaneous and sublingual immunotherapy may raise QoL among Atopic Dermatitis patients

A new study revealed that subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for aeroallergens improve the severity of the disease and also the quality of life in patients with atopic dermatitis. The study results were published in the journal of Allergy and Clinical Immunology. 

A combination of Skin barrier defects, immune dysregulation, and extrinsic stimuli like allergens, irritants, and microbes all contribute to atopic dermatitis (AD, eczema). But it is still unknown how environmental allergens (aeroallergens) cause AD. Allergen immunotherapy (AIT) which includes subcutaneous immunotherapy (SCIT), and sublingual immunotherapy (SLIT) are well established as safe and effective treatments to address allergies to aeroallergens for allergic rhinitis and allergic asthma. As there are mixed results from previous literature, researchers conducted a systematic review and meta-analysis regarding the benefits and harms of allergen immunotherapy (AIT) for AD. 

As part of the 2022 American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters AD Guideline update, databases like the MEDLINE, EMBASE, CENTRAL, CINAHL, LILACS, Global Resource for Eczema Trials, and Web of Science were searched from inception to December 2021.  Randomized controlled trials that compared SCIT, SLIT, and/or no AIT (placebo or standard care) for guideline panel–defined patient-important outcomes like the AD severity, itch, AD-related quality of life (QoL), flares, and adverse events were considered. Raters independently screened, extracted data, and assessed the risk of bias in duplicate. Intervention effects were synthesized using frequentist and Bayesian random-effects models. The GRADE approach determined the quality of evidence.